Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
PR Newswire•04/11/2026•08:55 ET
0
Key Highlights
- ➤Lucid Diagnostics (LUCD) to participate in Canaccord Genuity MedTech Forum November 11
- ➤CEO Lishan Aklog to join panel on oncology diagnostics reimbursement
- ➤Aklog and CFO Dennis McGrath available for investor one-on-one meetings
- ➤EsoGuard and EsoCheck target early detection of esophageal precancer
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire
NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 11, 2026 in New York City.
Get started
Create a free account to read the full story.